Prana appoints US analyst to board
Thursday, 25 March, 2004
Melbourne biotech company Prana Biotechnology (ASX: PBT) has appointed leading US biotech analyst Dr Jonas Alsenas to its board of directors.
Most recently, Alsenas managed a hedge fund with an emphasis on biotechnology for ING Investment Management, New York.
"[Alsenas] is held in high regard in the international biotech sector and possesses an extensive knowledge of the industry in which Prana operates. Hi understanding of, and fundamental belief in, our technology and business strategy will help to shape Prana's future," said Prana CEO Geoffrey Kempler.
Preventing neural graft rejection in Parkinson's patients
Researchers have engineered a way to fool the immune system into accepting neural grafts as part...
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
